$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-Q Financial Statement

#000119312514403316 Filed on November 07, 2014

Income Statement

Concept	2014 Q4	2014 Q3	2013 Q3
Revenue	$14.64M	$33.90M	$6.268M
YoY Change	117.02%	440.84%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.500M	$5.170M	$2.530M
YoY Change	75.2%	104.35%	60.13%
% of Gross Profit
Research & Development	$34.86M	$25.53M	$14.80M
YoY Change	128.14%	72.44%	51.08%
% of Gross Profit
Depreciation & Amortization	$400.0K	$300.0K	$400.0K
YoY Change	33.33%	-25.0%	0.0%
% of Gross Profit
Operating Expenses	$41.36M	$30.69M	$17.34M
YoY Change	117.8%	77.03%	52.37%
Operating Profit	-$26.73M	$3.208M	-$11.07M
YoY Change	118.32%	-128.98%	116.61%
Interest Expense	$90.00K	$50.00K	$10.00K
YoY Change	200.0%	400.0%	0.0%
% of Operating Profit		1.56%
Other Income/Expense, Net
YoY Change
Pretax Income	-$26.64M	$3.256M	-$11.06M
YoY Change	118.18%	-129.45%	116.91%
Income Tax	$20.00K	-$448.0K	$121.0K
% Of Pretax Income		-13.76%
Net Earnings	-$26.66M	$3.704M	-$11.18M
YoY Change	115.34%	-133.14%	140.62%
Net Earnings / Revenue	-182.18%	10.93%	-178.32%
Basic Earnings Per Share	-$0.76	$0.11	-$0.52
Diluted Earnings Per Share	-$0.76	$0.10	-$0.52
COMMON SHARES
Basic Shares Outstanding	34.68M shares	34.50M shares	22.74M shares
Diluted Shares Outstanding		36.59M shares	22.74M shares

Balance Sheet

Concept	2014 Q4	2014 Q3	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$342.1M	$220.0M	$195.0M
YoY Change	105.11%	12.81%
Cash & Equivalents	$14.03M	$70.05M	$106.0M
Short-Term Investments	$328.0M	$149.9M	$88.90M
Other Short-Term Assets	$8.600M	$8.800M	$3.800M
YoY Change	244.0%	131.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$2.334M
Total Short-Term Assets	$359.5M	$247.6M	$198.8M
YoY Change	111.81%	24.52%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.386M	$3.677M	$3.551M
YoY Change	69.93%	3.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$125.4M	$17.90M	$13.40M
YoY Change	362.73%	33.58%
Other Assets	$590.0K	$454.0K	$11.00K
YoY Change	14650.0%	4027.27%
Total Long-Term Assets	$132.4M	$22.05M	$20.25M
YoY Change	320.75%	8.87%
TOTAL ASSETS
Total Short-Term Assets	$359.5M	$247.6M	$198.8M
Total Long-Term Assets	$132.4M	$22.05M	$20.25M
Total Assets	$491.9M	$269.6M	$219.1M
YoY Change	144.48%	23.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.07M	$6.225M	$2.140M
YoY Change	200.9%	190.89%
Accrued Expenses	$14.02M	$10.00M	$4.764M
YoY Change	112.88%	109.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$61.09M	$35.08M	$37.38M
YoY Change	65.42%	-6.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.400M	$26.80M	$262.0K
YoY Change	106566.67%	10129.01%
Total Long-Term Liabilities	$6.400M	$26.80M	$262.0K
YoY Change	106566.67%	10129.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$61.09M	$35.08M	$37.38M
Total Long-Term Liabilities	$6.400M	$26.80M	$262.0K
Total Liabilities	$67.50M	$61.90M	$37.64M
YoY Change	82.75%	64.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$166.9M	-$140.3M	-$101.1M
YoY Change	47.16%	38.81%
Common Stock	$591.4M	$348.0M	$243.6M
YoY Change	141.46%	42.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$424.4M	$207.7M	$142.6M
YoY Change
Total Liabilities & Shareholders Equity	$491.9M	$269.6M	$219.1M
YoY Change	144.48%	23.07%

Cashflow Statement

Concept	2014 Q4	2014 Q3	2013 Q3
OPERATING ACTIVITIES
Net Income	-$26.66M	$3.704M	-$11.18M
YoY Change	115.34%	-133.14%	140.62%
Depreciation, Depletion And Amortization	$400.0K	$300.0K	$400.0K
YoY Change	33.33%	-25.0%	0.0%
Cash From Operating Activities	-$7.800M	-$23.50M	-$15.00M
YoY Change	-42.65%	56.67%	31.58%
INVESTING ACTIVITIES
Capital Expenditures	-$1.500M	-$600.0K	-$100.0K
YoY Change	650.0%	500.0%	-90.91%
Acquisitions
YoY Change
Other Investing Activities	-$285.8M	-$14.50M	-$80.60M
YoY Change	1314.85%	-82.01%	16020.0%
Cash From Investing Activities	-$287.3M	-$15.10M	-$80.70M
YoY Change	1308.33%	-81.29%	4647.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	239.1M	400.0K	124.2M
YoY Change	-59875.0%	-99.68%
NET CHANGE
Cash From Operating Activities	-7.800M	-23.50M	-15.00M
Cash From Investing Activities	-287.3M	-15.10M	-80.70M
Cash From Financing Activities	239.1M	400.0K	124.2M
Net Change In Cash	-56.00M	-38.20M	28.50M
YoY Change	62.79%	-234.04%	-317.56%
FREE CASH FLOW
Cash From Operating Activities	-$7.800M	-$23.50M	-$15.00M
Capital Expenditures	-$1.500M	-$600.0K	-$100.0K
Free Cash Flow	-$6.300M	-$22.90M	-$14.90M
YoY Change	-52.99%	53.69%	44.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q1	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	-3800000
CY2014Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34683082	shares
CY2014Q2	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	-700000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106011000
CY2013Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0
CY2014Q3	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	-400000
CY2014Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34642539	shares
CY2014Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34642539	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3373444	shares
CY2014Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	60	Securities
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.74
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1635445	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.02
CY2014Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	13.67
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2014Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	0	Securities
CY2014Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3816834	shares
CY2014Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	677000
CY2014Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	26352000
CY2014Q3	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	15826000
CY2014Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2014Q3	us-gaap	Liabilities Current LiabilitiesCurrent	35084000
CY2014Q3	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1400000
CY2014Q3	us-gaap	Common Stock Value CommonStockValue	35000
CY2014Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6225000
CY2014Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140284000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4405000
CY2014Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	347947000
CY2014Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	51000
CY2014Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10004000
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	207749000
CY2014Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1035000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	33257000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4493000
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4318000
CY2014Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	269608000
CY2014Q3	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	-400000
CY2014Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2014Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1271000
CY2014Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	18847000
CY2014Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2014Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3538000
CY2014Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3273000
CY2014Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	423000
CY2014Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	61000
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70049000
CY2014Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3677000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	181726000
CY2014Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	167838000
CY2014Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	21500000
CY2014Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	17917000
CY2014Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4990000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	160838000
CY2014Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	18759000
CY2014Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	0
CY2014Q3	us-gaap	Contracts Receivable Claims And Uncertain Amounts ContractsReceivableClaimsAndUncertainAmounts	18700000
CY2014Q3	us-gaap	Lease Incentive Receivable LeaseIncentiveReceivable	11200000
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	97023000
CY2014Q3	us-gaap	Assets Assets	269608000
CY2014Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	149921000
CY2014Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	167787000
CY2014Q3	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2014Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	10000
CY2014Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	3841000
CY2014Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	454000
CY2014Q3	us-gaap	Assets Current AssetsCurrent	247560000
CY2014Q3	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2014Q3	agio	One Time Receivable Eligibility Upon Dosing Of Last Patient Under First Split Licensed Program OneTimeReceivableEligibilityUponDosingOfLastPatientUnderFirstSplitLicensedProgram	25000000
CY2014Q3	agio	Accrued Contracted Research And Development Costs Current AccruedContractedResearchAndDevelopmentCostsCurrent	4425000
CY2014Q3	agio	Extension Payment Receivable ExtensionPaymentReceivable	20000000
CY2014Q3	agio	Potential Milestone Payment Receivable Upon Early Clinical Development Milestone Event PotentialMilestonePaymentReceivableUponEarlyClinicalDevelopmentMilestoneEvent	22500000
CY2014Q3	agio	Operating Lease Area OperatingLeaseArea	74498	sqft
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10700000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	91297000
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31202542	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31202542	shares
CY2013Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	33	Securities
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.14
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2013Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	0	Securities
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3846168	shares
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9000
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	32567000
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	123000
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36930000
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	31000
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3678000
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113444000
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	244881000
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	14000
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6586000
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	131482000
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6000
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	140000
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	201205000
CY2013Q4	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	-700000
CY2013Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2013Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	320000
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	25072000
CY2013Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	1462000
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3642000
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	220000
CY2013Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	20000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71560000
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3758000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	76189000
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	122334000
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	31700000
CY2013Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	27125000
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2502000
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	571000
CY2013Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	476000
CY2013Q4	us-gaap	Assets Assets	201205000
CY2013Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	95209000
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	122320000
CY2013Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6000
CY2013Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4000
CY2013Q4	us-gaap	Assets Current AssetsCurrent	169747000
CY2013Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2013Q4	agio	Accrued Contracted Research And Development Costs Current AccruedContractedResearchAndDevelopmentCostsCurrent	2484000
CY2013Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	19731564	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.83
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-42783000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M10D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0123	pure
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10111735	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.08
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9260	pure
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3942500	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10111735	shares
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	119498000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-81000
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-26615000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-26641000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26998000
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	18804000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1075000
	us-gaap	Net Income Loss NetIncomeLoss	-27025000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	26000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31187000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1684000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1865000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18804000
	us-gaap	Operating Expenses OperatingExpenses	45445000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39223000
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	382000
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	4162000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	14714000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2480000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	410000
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	410000
	us-gaap	Depreciation Depreciation	1100000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	124304000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124204000
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	115923000
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-66807000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	410000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1600000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6222000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1178000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	53766000
	us-gaap	Share Based Compensation ShareBasedCompensation	1865000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
	agio	Public Offering Costs Included In Accounts Payable PublicOfferingCostsIncludedInAccountsPayable	474000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<p> In July 2014, the Company amended its collaboration agreement with Celgene. As a result of the amendment, the Company was required to reevaluate the agreement under Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2009-13, <i style="FONT-SIZE: 13px; FONT-FAMILY: 'Times New Roman'; FONT-VARIANT: normal; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); LETTER-SPACING: normal; LINE-HEIGHT: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">Multiple-Element Revenue Arrangements</i> (“ASU No. 2009-13”). The amendment was determined to be a material modification pursuant to ASU <font style="WHITE-SPACE: nowrap; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 13px 'Times New Roman'; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">No. 2009-13,</font> and the Company will recognize revenue for the arrangement under this guidance on a prospective basis, as discussed in Note 5.</p>
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y6M26D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.42
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
	dei	Trading Symbol TradingSymbol	AGIO
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	24.30
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-51578000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	78002	shares
	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3636	pure
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2.75
	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1176733	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0183	pure
	dei	Document Period End Date DocumentPeriodEndDate	2014-09-30
	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	12.75
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33176801	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	50722000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	727000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	33.23
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8477	pure
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3829961	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1128065	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33176801	shares
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	215383000
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	121200000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-412000
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27288000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-27406000
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	18283000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26803000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	5958000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26840000
	us-gaap	Net Income Loss NetIncomeLoss	-26840000
	us-gaap	Investment Income Interest InvestmentIncomeInterest	118000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	37000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2756000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	197000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6752000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12439000
	us-gaap	Operating Expenses OperatingExpenses	78128000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65509000
	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5303000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1511000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3414000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-448000
	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-448000
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	571000
	us-gaap	Depreciation Depreciation	1005000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	96101000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	94685000
	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-46034000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1416000
	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-448000
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1800000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12619000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2354000
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	169505000
	us-gaap	Share Based Compensation ShareBasedCompensation	6778000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	44800000
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
	agio	Period Considered For Agreement Termination Notice PeriodConsideredForAgreementTerminationNotice	P30D
	agio	Operating Leases Number Of Renewal Options For Extended Term OperatingLeasesNumberOfRenewalOptionsForExtendedTerm	2	Lease
	agio	Date Of Extension Of Discovery Phase DateOfExtensionOfDiscoveryPhase	2016-04
	agio	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	80000
	agio	Number Of Licensed Programs Type Under Collaboration Agreements NumberOfLicensedProgramsTypeUnderCollaborationAgreements	3	Licensed_Program
	agio	Number Of Development Candidates Nominated By Joint Research Committee NumberOfDevelopmentCandidatesNominatedByJointResearchCommittee	2	Candidate
	agio	Vesting Of Restricted Stock Value VestingOfRestrictedStockValue	7000
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	184000
CY2010Q2	agio	Research Collaborative Arrangement Expiration Period ResearchCollaborativeArrangementExpirationPeriod	2014-04
CY2010Q2	agio	Agreement Amended Period AgreementAmendedPeriod	2011-10
CY2010Q2	agio	Discover Period Under Collaboration Agreement DiscoverPeriodUnderCollaborationAgreement	P2Y
CY2011Q4	agio	Receipt Due To Agreement Amendment ReceiptDueToAgreementAmendment	20000000
CY2011Q4	agio	Initial Agreement Period InitialAgreementPeriod	P3Y
CY2011Q4	agio	Extended Agreement Period ExtendedAgreementPeriod	P4Y
CY2014Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	5958000
CY2014Q1	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	1500000
CY2014Q2	agio	Receipt Due To Agreement Amendment ReceiptDueToAgreementAmendment	20000000
CY2013Q4	agio	Date Of Extension Of Discovery Phase DateOfExtensionOfDiscoveryPhase	2016-04
CY2013Q4	agio	Initial Agreement Period InitialAgreementPeriod	P4Y
CY2013Q4	agio	Research Collaborative Arrangement Expiration Period ResearchCollaborativeArrangementExpirationPeriod	2015-04
CY2013Q4	agio	Extended Agreement Period ExtendedAgreementPeriod	P5Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M5D
CY2013	agio	Initial Agreement Period InitialAgreementPeriod	P4Y
CY2013	agio	Research Collaborative Arrangement Expiration Period ResearchCollaborativeArrangementExpirationPeriod	2015-04
CY2013	agio	Extended Agreement Period ExtendedAgreementPeriod	P5Y
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.30
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2013Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M2D
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0173	pure
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22744486	shares
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9425	pure
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3942500	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22744486	shares
CY2013Q3	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11056000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11069000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11147000
CY2013Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	6268000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11744000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-11177000
CY2013Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	30000
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1112000
CY2013Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	17337000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14803000
CY2013Q3	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2013Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	567000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	121000
CY2013Q3	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	121000
CY2013Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2013Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	121000
CY2013Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2013Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2534000
CY2013Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	31.14
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0195	pure
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36592683	shares
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.11
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7889	pure
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1484917	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34495076	shares
CY2014Q3	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3256000
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	3208000
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3743000
CY2014Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	33900000
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3704000
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	3704000
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	48000
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	39000
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2866000
CY2014Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	30692000
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25526000
CY2014Q3	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-448000
CY2014Q3	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-448000
CY2014Q3	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit
CY2014Q3	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-448000
CY2014Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5166000
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	10000000
CY2014Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit

Files In Submission

Name	View Source	Status
0001193125-14-403316-index-headers.html	Edgar Link	pending
0001193125-14-403316-index.html	Edgar Link	pending
0001193125-14-403316.txt	Edgar Link	pending
0001193125-14-403316-xbrl.zip	Edgar Link	pending
agio-20140930.xml	Edgar Link	completed
agio-20140930.xsd	Edgar Link	pending
agio-20140930_cal.xml	Edgar Link	unprocessable
agio-20140930_def.xml	Edgar Link	unprocessable
agio-20140930_lab.xml	Edgar Link	unprocessable
agio-20140930_pre.xml	Edgar Link	unprocessable
d804161d10q.htm	Edgar Link	pending
d804161dex311.htm	Edgar Link	pending
d804161dex312.htm	Edgar Link	pending
d804161dex321.htm	Edgar Link	pending
d804161dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2014 Q4 Form 10-Q Financial Statement

#000119312514403316 Filed on November 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2014 Q4 Form 10-Q Financial Statement

#000119312514403316 Filed on November 07, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio